logo
1 of Wall Street's Favorite Stock Worth Your Attention and 2 to Question

1 of Wall Street's Favorite Stock Worth Your Attention and 2 to Question

Yahoo22-04-2025

The stocks in this article have caught Wall Street's attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because analysts typically say nice things about companies so their firms can win business in other product lines like M&A advisory.
Unlike the investment banks, we created StockStory to provide independent analysis that helps you determine which companies are truly worth following. Keeping that in mind, here is one stock where Wall Street's excitement appears well-founded and two where consensus estimates seem disconnected from reality.
Consensus Price Target: $283.58 (25.8% implied return)
Founded by J. Willard Marriott in 1927, Marriott International (NASDAQ:MAR) is a global hospitality company with a portfolio of over 7,000 properties and 30 brands, spanning 130+ countries and territories.
Why Is MAR Not Exciting?
Revenue per room has disappointed over the past two years due to weaker trends in its daily rates and occupancy levels
Estimated sales growth of 4.2% for the next 12 months implies demand will slow from its two-year trend
Earnings per share lagged its peers over the last five years as they only grew by 9.2% annually
At $218.52 per share, Marriott trades at 20.2x forward price-to-earnings. Check out our free in-depth research report to learn more about why MAR doesn't pass our bar.
Consensus Price Target: $9.38 (124% implied return)
Established in 1996, Pangaea Logistics (NASDAQ:PANL) specializes in global logistics and transportation services, focusing on the shipment of dry bulk cargoes.
Why Do We Think PANL Will Underperform?
Products and services are facing significant end-market challenges during this cycle as sales have declined by 12.4% annually over the last two years
Issuance of new shares over the last two years caused its earnings per share to fall by 40.2% annually, even worse than its revenue declines
Free cash flow margin dropped by 5.4 percentage points over the last five years, implying the company became more capital intensive as competition picked up
Pangaea's stock price of $4.19 implies a valuation ratio of 3.9x forward price-to-earnings. To fully understand why you should be careful with PANL, check out our full research report (it's free).
Consensus Price Target: $96.16 (65% implied return)
Pioneering treatments for conditions that often had no previous therapeutic options, BioMarin Pharmaceutical (NASDAQ:BMRN) develops and commercializes therapies that address the root causes of rare genetic disorders, particularly those affecting children.
Why Are We Positive On BMRN?
Annual revenue growth of 16.7% over the last two years was superb and indicates its market share increased during this cycle
Performance over the past five years shows its incremental sales were extremely profitable, as its annual earnings per share growth of 30.8% outpaced its revenue gains
Free cash flow margin grew by 18.6 percentage points over the last five years, giving the company more chips to play with
BioMarin Pharmaceutical is trading at $58.70 per share, or 14.6x forward price-to-earnings. Is now the right time to buy? Find out in our full research report, it's free.
The market surged in 2024 and reached record highs after Donald Trump's presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.
While the crowd speculates what might happen next, we're homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver's seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 175% over the last five years.
Stocks that made our list in 2019 include now familiar names such as Nvidia (+2,183% between December 2019 and December 2024) as well as under-the-radar businesses like Sterling Infrastructure (+1,096% five-year return). Find your next big winner with StockStory today for free.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results
Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results

Yahoo

time15 minutes ago

  • Yahoo

Metsera Unveils First-in-Class Once-Monthly Amylin Candidate MET-233i's Positive Phase 1 Results

Metsera, Inc. (NASDAQ:MTSR) is one of the 13 Biotech Stocks with Huge Upside Potential. Metsera, Inc. (NASDAQ:MTSR) reported encouraging Phase 1 results for MET-233i, its once-monthly amylin analog, which showed a mean weight loss of up to 8.4% at Day 36 after subtracting the placebo. A laboratory technician researching a sample of cells in a biotechnology laboratory. The candidate supported monthly dosing with the longest half-life of any known amylin analog, 19 days. MET-233i had no safety indications and was well tolerated. The trial included 80 overweight or obese participants, with individual cases resulting in weight loss of up to 10.2%. MET-233i displayed high tolerability and dose-linear pharmacokinetics when tested in both single and multiple ascending dose formats. The majority of adverse gastrointestinal events occurred in the first week and were mild and dose-dependent. According to preliminary findings, it might make it practical to use its fully-biased GLP-1 RA candidate, MET-097i, in the first monthly GLP-1 + amylin combination therapy. Topline results from combination trials and an ongoing monotherapy study with MET-097i are anticipated in late 2025. Metsera, Inc. (NASDAQ:MTSR)'s HALO™ peptide stabilization platform supports the program. Metsera, Inc. (NASDAQ:MTSR) is a clinical-stage biopharmaceutical business focused on developing new treatments for obesity and metabolic diseases. It is one of the stocks with the biggest upside. While we acknowledge the potential of MTSR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 10 High-Growth EV Stocks to Invest In and 13 Best Car Stocks to Buy in 2025. Disclosure. None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Why Palantir Technologies Hit a New All-Time High on Wednesday
Why Palantir Technologies Hit a New All-Time High on Wednesday

Yahoo

time29 minutes ago

  • Yahoo

Why Palantir Technologies Hit a New All-Time High on Wednesday

One Wall Street analyst boosted Palantir's price target, despite maintaining a sell rating. The reasoning for the move was decidedly bullish. The key factor in the rating is Palantir's frothy valuation. 10 stocks we like better than Palantir Technologies › Palantir Technologies (NASDAQ: PLTR) stock continued its epic run on Wednesday, climbing as much as 5.4%. As of 3:37 p.m. ET, the stock was still up 3%. The artificial intelligence (AI) software and data mining specialist has climbed to new heights several times in recent weeks, with its stock notching a new all-time high on Wednesday. That puts the stock up more than 80% so far this year. The catalyst behind today's move was a reluctant nod from a Wall Street analyst. Mizuho analyst Matthew Broome kept an underperform (sell) rating on Palantir stock, but raised his price target for Palantir to $116, up from its previous level of $94. For those keeping score at home, that's roughly 12% below the stock's closing price on Tuesday, so the analyst is obviously playing catch-up. Broome cited Palantir's "strong recent execution and significant upward revisions" for his price target increase. The analyst also noted the company's "strong strategic positioning with large customers and potential for further accelerated growth in future years." So, if the analyst is so bullish on Palantir, why maintain the sell rating? In a word: valuation. Palantir stock is currently selling for 594 times earnings and 109 times sales. With multiples of that magnitude, it isn't for the faint of heart. Even factoring in the company's accelerating growth, it sports a price-to-earnings growth (PEG) ratio of 6, when any number higher than 1 is overvalued. Don't get me wrong: I'm a dyed-in-the-wool Palantir bull. However, valuation is a fickle mistress, and any failure by the company to execute -- real or perceived -- could bring the stock crashing down. In fact, I wouldn't be surprised to see Palantir stock get cut in half at some point over the next year -- before climbing to even greater heights. Before you buy stock in Palantir Technologies, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Palantir Technologies wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $649,102!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $882,344!* Now, it's worth noting Stock Advisor's total average return is 996% — a market-crushing outperformance compared to 174% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Danny Vena has positions in Palantir Technologies. The Motley Fool has positions in and recommends Palantir Technologies. The Motley Fool has a disclosure policy. Why Palantir Technologies Hit a New All-Time High on Wednesday was originally published by The Motley Fool

RadNet Secures $100 Million Incremental Term Loan to Fund Acquisitions and Corporate Initiatives
RadNet Secures $100 Million Incremental Term Loan to Fund Acquisitions and Corporate Initiatives

Yahoo

timean hour ago

  • Yahoo

RadNet Secures $100 Million Incremental Term Loan to Fund Acquisitions and Corporate Initiatives

LOS ANGELES, June 11, 2025 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) ('RadNet'), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services, today announced that it has entered into Incremental Amendment No. 2 (the 'Second Amendment') to its Third Amended and Restated First Lien Credit and Guaranty Agreement, as amended (the 'Existing Credit Agreement' and, as amended by the Second Amendment, the 'Credit Agreement'). Pursuant to the Second Amendment, Barclays Bank PLC, as lender, committed to provide RadNet an incremental term loan in the aggregate principal amount of $100.0 million (the '2025 Incremental Term Loan'), which will be added to and form a part of the existing term loan under the Existing Credit Agreement (the 'Existing Term Loan,' together with the 2025 Incremental Term Loan, the 'Term Loan'). The 2025 Incremental Term Loan will mature on April 18, 2031—coincident with the maturity date of the $868.4 million balance of the Existing Term Loan under the Existing Credit Agreement. Quarterly payments of principal on the Term Loan will be approximately $2.4 million compared to approximately $2.2 million prior to the entry of the Second Amendment. All other terms and covenants of the Credit Agreement (as amended by the Second Amendment) remain unchanged. The proceeds of the 2025 Incremental Term Loan will be used to finance future acquisitions and for other general corporate purposes, providing RadNet with additional flexibility to pursue strategic growth opportunities across its national imaging center network and technology platforms. Mark Stolper, Executive Vice President and Chief Financial Officer of RadNet, commented, 'We appreciate the continued support of Barclays and our relationship banks and term-loan lenders. This incremental financing increases our capacity to execute on a pipeline of acquisition opportunities while maintaining our conservative capital structure. The proceeds of approximately $100 million adds to the $717 million cash balance as of March 31, 2025, positioning us to advance our growth strategy and create long-term value for our stockholders.'RadNet, Inc. is a leading national provider of freestanding, fixed-site diagnostic imaging services in the United States based on the number of locations and annual imaging revenue. RadNet has a network of 401 owned and/or operated outpatient imaging centers. RadNet's imaging center markets include Arizona, California, Delaware, Florida, Maryland, New Jersey, New York and Texas. In addition, RadNet provides radiology information technology and artificial intelligence solutions marketed under the DeepHealth brand, teleradiology professional services and other related products and services to customers in the diagnostic imaging industry. Together with contracted radiologists, and inclusive of full-time and per diem employees and technologists, RadNet has a total of over 11,000 employees. For more information, visit

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store